At the last EU Standing Committee meeting of 22nd October 2007, the European Commission has granted DSM Nutritional Products an extension to the approval given to its phytase feed enzyme, RONOZYME® P, for ducks.

RONOZYME® P (Granulate and liquid) is now approved for salmonids, broiler, layer, turkey, duck, sow, piglet and fattening pigs. The large spectrum of EU authorizations is of major added-value for multi-species feed factories. The European Food Safety Authority (EFSA), in charge of scientific evaluation had confirmed the efficacy and the safety of the RONOZYME® P for ducks in its opinion of 10th July 2007.

RONOZYME® P5000 (CT) is the most heat stable phytase granulate product for feed. It is dust free and free flowing to ensure safety and good handling properties. RONOZYME® P5000 (CT) is the best in class in respect to particle size which allows very good mixing properties in all premix and feed. Physical properties coupled with the outstanding and proven thermo-stability characteristics have been maintained which allow it to be used successfully at high feed processing temperatures (90-95°C). These characteristics that are unique to RONOZYME® P5000 (CT) are ensuring consistent delivery of phytase to the animals day after day. For the best economic returns, DSM recommends using RONOZYME® P 5000 in diets for ducks at a level of 150 g/tonne.

The RONOZYME® product ranges of feed enzymes are developed within the alliance of DSM Nutritional Products and the Danish company Novozymes. DSM Nutritional Products adds value to the food chain through the provision of innovative solutions based on providing maximum safety, quality, traceability and reliability benefiting our customers, the consumer, the environment and animal welfare.

About Novozymes

Novozymes is the world leader in bio-innovations. Together with customers across a broad array of industries, Novozymes creates tomorrow's industrial bio-solutions, which both improves its customers' business and the use of the planet's resources.

About DSM Nutritional Products

DSM Nutritional Products is the world's leading supplier of vitamins, carotenoids and other fine chemicals to the feed, food, pharmaceutical and personal care industries. The business has sales of about EUR 2 billion and a long tradition as a pioneer in the discovery of new products, new formulations and attractive applications for all industry segments. For further company information please visit www.dsmnutritionalproducts.com

About DSM

DSM is active worldwide in nutritional and pharma ingredients, performance materials and industrial chemicals. The company develops, produces and sells innovative products and services that help improve the quality of life. DSM’s products are used in a wide range of end-markets and applications, such as human and animal nutrition and health, personal care, pharmaceuticals, automotive and transport, coatings and paint, housing and electrics & electronics (E&E). DSM’s strategy, named Vision 2010 – Building on Strengths, focuses on accelerating profitable and innovative growth of the company’s specialties portfolio. The key drivers of this strategy are market-driven growth and innovation plus an increased presence in emerging economies. The group has annual sales of over €8 billion and employs some 22,000 people worldwide. DSM ranks among the global leaders in many of its fields. The company is headquartered in the Netherlands, with locations in Europe, Asia, Africa, Australia and the Americas. More information about DSM can be found at www.dsm.com

For more information:
DSM Nutritional Products
Charlotte Frederiksen

Tel. +41 (0) 61 688 85 14
Fax +41 (0) 61 687 37 16

E-mail: charlotte.frederiksen@dsm.com

Forward-looking statements

This press release contains forward-looking statements. These statements are based on current expectations, estimates and projections of DSM management and information currently available to the company. The statements involve certain risks and uncertainties that are difficult to predict and therefore DSM does not guarantee that its expectations will be realized. Furthermore, DSM has no obligation to update the statements contained in this press release.